A new semisynthetic analogue ABL-L was prepared and demonstrated to show stronger suppression against HEp-2 cells.
ABL-L-induced inhibition of cell proliferation was associated with an increase in G1-phase arrest of HEp-2 cells.
ABL-L inhibits the malignant behaviors of HEp-2 cells via a p53-dependent, caspase-mediated pathway.